[en] BACKGROUND In wild-type transthyretin cardiac amyloidosis (ATTRwt-CM), the prognostic role of carpal tunnel syndrome (CTS) is unclear and that of lumbar spinal stenosis (SS) remains unexplored. OBJECTIVES The aim was to examine the diagnostic, therapeutic, and prognostic relevance of bilateral CTS and SS in ATTRwt-CM, in relation to the tafamidis treatment. METHODS Clinical characteristics of 1,449 patients with ATTRwt-CM were evaluated in a multicenter cohort. The primary endpoint was all-cause mortality. Cox multivariable regression was used to assess mortality in patients with and without CTS and SS. RESULTS Preceding an ATTRwt-CM diagnosis, CTS and SS were present in 29% and 22% of patients, respectively, without sex-difference. CTS (P < 0.001), but not SS, was more prevalent among younger patients. Tenosynovial red flags and ATTRwt-CM diagnosis occurred approximately 4 years later in females vs males, with similar preceding time, suggesting later female ATTRwt-CM disease onset. Patients with vs without CTS and SS had lower National Amyloidosis Centre disease stage (P # 0.001), despite similar symptomatic status. During a mean follow-up of 2.3 ± 1.8 years, 73% (1,052/1,449) of patients were initiated on tafamidis and 28% (406) died. Tafamidis was initiated more in CTS positive vs negative patients (78% vs 71%; P = 0.008), on average 2.3 years earlier (P < 0.001). More SS positive than negative patients received tafamidis (78% vs 71%; P = 0.018), but at similar age (P = 0.394). CTS (HR: 0.70; 95% CI: 0.52-0.95) and SS (HR: 0.68; 95% CI: 0.48-0.97) predicted lower mortality. CONCLUSIONS Both CTS and SS not only enable early ATTRwt-CM diagnosis and treatment initiation, but independently relate to improved survival, potentiating a role for opportunistic screening.
Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142:e7-e22.
Ruiz-Hueso R, Salamanca-Bautista P, Quesada-Simon MA, Yun S, Conde-Martel A, Morales-Rull JL, et al. Estimating the Prevalence of Cardiac Amyloidosis in Old Patients with Heart Failure-Barriers and Opportunities for Improvement: The PREVAMIC Study. J Clin Med. 2023;12.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007-1016.
Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, et al. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC Heart Fail. 2021;9:115-123.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021.
Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23:58-63.
Fosbol EL, Rorth R, Leicht BP, Schou M, Maurer MS, Kristensen SL, et al. Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular Outcomes. J Am Coll Cardiol. 2019;74:15-23.
Debonnaire P, Claeys M, De Smet M, Trenson S, Lycke M, Demeester C, et al. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications. Acta Cardiol. 2021:1-14.
Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020;22:507-515.
Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018;72:2040-2050.
Klarskov VR, Ladefoged BT, Pedersen ALD, Hartig-Andreasen C, Clemmensen TS and Poulsen SH. Clinical characteristics and prognostic implications of orthopedic ligament disorders in patients with wild-type transthyretin amyloidosis cardiomyopathy. J Cardiol. 2023;82:122-127.
Aus dem Siepen F, Hein S, Prestel S, Baumgartner C, Schonland S, Hegenbart U, et al. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol. 2019;108:1324-1330.
Nitsche C, Ioannou A, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2024;26:2008-2012.
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016;68:1014-1020.
Law S, Bezard M, Petrie A, Chacko L, Cohen OC, Ravichandran S, et al. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. Eur Heart J. 2022;43:2622-2632.
Westin O, Fosbol EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, et al. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. J Am Coll Cardiol. 2022;80:967-977.
Katz JN, Zimmerman ZE, Mass H and Makhni MC. Diagnosis and Management of Lumbar Spinal Stenosis: A Review. JAMA. 2022;327:1688-1699.
Padua L, Cuccagna C, Giovannini S, Coraci D, Pelosi L, Loreti C, et al. Carpal tunnel syndrome: updated evidence and new questions. Lancet Neurol. 2023;22:255-267.
Jensen RK, Jensen TS, Koes B and Hartvigsen J. Prevalence of lumbar spinal stenosis in general and clinical populations: a systematic review and meta-analysis. Eur Spine J. 2020;29:2143-2163.
Genova A, Dix O, Saefan A, Thakur M and Hassan A. Carpal Tunnel Syndrome: A Review of Literature. Cureus. 2020;12:e7333.
Westin O, Fosbol E and Gustafsson F. Refining the role of carpal tunnel syndrome in cardiac amyloidosis. Eur J Heart Fail. 2020;22:516-518.
Aimo A, Panichella G, Garofalo M, Gasparini S, Arzilli C, Castiglione V, et al. Sex differences in transthyretin cardiac amyloidosis. Heart Fail Rev. 2023.
Debonnaire P, Dujardin K, Verheyen N, Pouleur AC, Droogmans S, Claeys M, et al. Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study. Eur Heart J. 2025;46:1057-1070.
Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390:132-142.
Noory N, Havers-Borgersen E, Yafasova A, Westin O, Maurer MS, Kober L, et al. Previous surgery for lumbar spinal stenosis and association with amyloidosis and heart failure - A Danish nationwide study. Amyloid. 2025:1-7.
Vianello PF, La Malfa G, Tini G, Mazzola V, Miceli A, Santolini E, et al. Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: The ACTUAL study. Int J Cardiol. 2021;329:144-147.
Zegri-Reiriz I, de Haro-Del Moral FJ, Dominguez F, Salas C, de la Cuadra P, Plaza A, et al. Prevalence of Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome. J Cardiovasc Transl Res. 2019;12:507-513.
Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011;42:1785-1791.
Ladefoged B, Clemmensen T, Dybro A, Hartig-Andreasen C, Kirkeby L, Gormsen LC, et al. Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS). ESC Heart Fail. 2022.
Debonnaire P, Claeys M, De Paepe P, Christiaen E, Geerts B, De Geeter F, et al. Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients: Results of the CASS Study. JACC CardioOncol. 2023;5:836-838.
Westermark P, Westermark GT, Suhr OB and Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014;119:223-228.
Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015;28:201-207.
Godara A, Riesenburger RI, Zhang DX, Varga C, Fogaren T, Siddiqui NS, et al. Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid. 2021;28:226-233.
Eldhagen P, Berg S, Lund LH, Sorensson P, Suhr OB and Westermark P. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J Intern Med. 2020.
Maurer MS, Smiley D, Simsolo E, Remotti F, Bustamante A, Teruya S, et al. Analysis of lumbar spine stenosis specimens for identification of amyloid. J Am Geriatr Soc. 2022.
